Resonance across cultures and faiths: examining the violin music’s role in emotional, psychological, and spiritual well-being for sustainable societies
Identifying clinical features associated with electroconvulsive therapy response in adolescents with major depressive disorder using machine learning
A two-decade bibliometric analysis (2004–2024) of parental factors in the context of internet gaming disorder research
Trends of incident stimulant use disorder diagnoses before and after the COVID-19 pandemic in British Columbia (2013-2024): a population-based study
Newcomer anti-IL-33 makes strides in COPD
Nature Biotechnology, Published online: 07 May 2026; doi:10.1038/s41587-026-03136-x
AstraZeneca’s IL-33 antibody tozorakimab targets two distinct signaling pathways engaged in COPD: inflammation and epithelial dysfunction.
STAT+: FDA to reconsider treatment for rare cancer after its surprise rejection
Two companies developing a therapy for a rare blood cancer have reached an agreement with the Food and Drug Administration that walked back the agency’s main reason for rejecting the drug in January.
Pierre Fabre Pharmaceuticals and Atara Biotherapeutics, makers of the drug called Ebvallo, said Thursday that a meeting held in late April with FDA officials ended with the agency agreeing that their already completed, single-arm clinical trial was sufficient to support a review and potential approval.
When the FDA rejected Ebvallo, the agency said the same study was flawed and the data produced from it was “insufficient” to support the drug’s approval. The drug’s review was conducted by the FDA’s Center for Biologics Evaluation and Research, led at the time by Vinay Prasad. He departed the agency at the end of April.
Hospital shootings steadily increased since 2000
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.
Good morning. I was charmed by this profile of tween life in America, both as a former tween girl and as a reporter. I laughed out loud at one tween asking her friend, the main subject of the story: “You’re still getting interviewed?”
STAT+: Next-gen Duchenne drug from Entrada disappoints
Entrada Therapeutics’ next-generation drug for Duchenne muscular dystrophy disappointed in an early trial, raising questions about the company’s competitiveness in an increasingly crowded field.
Entrada is one of a group of companies developing new exon-skipping drugs. These medicines are designed to help patients with certain mutations produce shortened but still functional forms of dystrophin, the protein missing in Duchenne.
The first such drug, from Sarepta Therapeutics, had only marginal effects on protein production but was approved in 2016 under immense pressure from patient advocates. Since then, scientists have devised ways of redesigning these molecules to better infiltrate muscle cells, leading to vastly higher dystrophin levels.
STAT+: Color me skeptical: Drinking gold is not an ALS cure
This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.
It’s been a while since I wrote a “Mean Adam” newsletter.
The biotech company Clene is developing a treatment for ALS called CNM-Au8 that it describes as a “highly concentrated aqueous suspension of catalytically-active, clean-surfaced, faceted gold nanocrystals.”
Allow me to translate: The Clene “drug” is gold microdust suspended in water.

